A Pleasanton company whose implanted medical device opens the urinary tract for men with an enlarged prostate won a key government payment decision, the company said Monday.
The Centers for Medicare and Medicaid Services approved so-called terminology codes for UroLift, a system developed by privately held NeoTract Inc. that is designed to treat a condition known as benign prostatic hyperplasia, or BPH.
The CMS decision is important for NeoTract, company President and CEO Dave Amerson said, because roughly seven of every 10 men with BPH are Medicare age.
Help employers find you! Check out all the jobs and post your resume.
The Centers for Medicare and Medicaid Services approved so-called terminology codes for UroLift, a system developed by privately held NeoTract Inc. that is designed to treat a condition known as benign prostatic hyperplasia, or BPH.
The CMS decision is important for NeoTract, company President and CEO Dave Amerson said, because roughly seven of every 10 men with BPH are Medicare age.
Help employers find you! Check out all the jobs and post your resume.
